OSE Immunotherapeutics SA announced that the Company has entered into a commercial and revenue sharing agreement with leading global cancer center. This exclusive and worldwide agreement with Memorial Sloan Kettering Cancer Center covers OSE Immunotherapeutics? patent rights and jointly owned OSE/MSK patent rights in the field of Chimeric Antigen Receptor (CAR) cell therapy for the treatment of Interleukin-7 Receptor (IL-7R) expressing cancers, in particular hematological tumors such as Acute Lymphoblastic Leukemia.

As part of this agreement, MSK will lead the research, development, and commercialization efforts, and subsequently share potential future revenues with OSE Immunotherapeutics. This new agreement is based on the initial multi-year research collaboration between MSK and OSE Immunotherapeutics to explore the preclinical potential of a non-antagonist IL-7R monoclonal antibody directed against the alpha chain of IL-7R used either as a therapeutic antibody or for the design of innovative CAR-T cells for cancer indications expressing high level of IL-7R.